secwatch.observer — SEC 8-K summary
======================================

Issuer:     Ultragenyx Pharmaceutical Inc. (RARE)
CIK:        0001515673
Form:       8-K
Filed at:   2022-11-02T23:59:59+00:00
Accession:  0000950170-22-021238
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Ultragenyx Q3 revenue $90.7M, net loss $245.1M ($3.50) on GeneTx charge; reaffirms FY guidance
--------------------------------------------------------------------------------

- Total revenue $90.7M (+11% YoY) driven by Crysvita $64.5M (+28% YoY) and Dojolvi $13.3M.
- Net loss $245.1M vs $73.0M in Q3 2021; includes $75.2M R&D expense for GeneTx acquisition.
- Cash & marketable debt securities $996.2M as of Sep 30, includes $491M from OMERS Crysvita royalty sale.
- FY 2022 guidance reaffirmed: Crysvita territories $250-$260M, Dojolvi $55-$65M.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1515673/000095017022021238/0000950170-22-021238-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1515673/000095017022021238/rare-20221102.htm
  HTML page:      https://secwatch.observer/filing/0000950170-22-021238

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer